TransMedics Group's (TMDX) "Hold" Rating Reiterated at Needham & Company LLC

Key Points

• TransMedics Group's stock received a "hold" rating from Needham & Company, but several other analysts have recently issued higher price targets, with Oppenheimer increasing their target to $150.00.
• Shares of TransMedics Group fell by 2.5%, closing at $116.84, amid active trading with over 210,000 shares exchanged.
• The company reported a 37.7% year-over-year revenue increase, with a quarterly profit of $0.92 per share, surpassing analysts' expectations.

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reissued by equities researchers at Needham & Company LLC in a research report issued on Monday,Benzinga reports.

Other analysts have also recently issued reports about the company. Oppenheimer boosted their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

TransMedics Group Trading Down 1.5%

TMDX traded down $1.76 during mid-day trading on Monday, reaching $114.96. The stock had a trading volume of 665,581 shares, compared to its average volume of 998,422. The stock has a market capitalization of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm's fifty day simple moving average is $120.24 and its two-hundred day simple moving average is $102.84. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $172.78.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same quarter in the previous year, the company posted $0.35 earnings per share. The firm's quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of the business. Opal Wealth Advisors LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC bought a new stake in shares of TransMedics Group during the second quarter worth $48,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of TransMedics Group during the second quarter worth $48,000. NBC Securities Inc. acquired a new stake in shares of TransMedics Group during the first quarter worth $25,000. Finally, Smartleaf Asset Management LLC lifted its position in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.